Literature DB >> 26242461

Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.

S Ferrero1,2, A Pastore1, C W Scholz3, R Forstpointner1, A Pezzutto4, L Bergmann5, L Trümper6, J Finke7, U Keller8, P Ghione2, R Passera9, W Hiddemann1, O Weigert1, M Unterhalt1, M Dreyling1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26242461     DOI： 10.1038/leu.2015.215

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers.

Authors:  Francesco Zaja; Stefano De Luca; Umberto Vitolo; Lorella Orsucci; Alessandro Levis; Flavia Salvi; Chiara Rusconi; Erika Ravelli; Alessandra Tucci; Chiara Bottelli; Monica Balzarotti; Ercole Brusamolino; Maurizio Bonfichi; Stefano A Pileri; Elena Sabattini; Stefano Volpetti; Chiara Monagheddu; Angelo Vacca; Roberto Ria; Renato Fanin
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

3.  Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.

Authors:  Thomas E Witzig; Arturo Molina; Leo I Gordon; Christos Emmanouilides; Russell J Schilder; Ian W Flinn; Mohamed Darif; Roger Macklis; Katie Vo; Gregory A Wiseman
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

4.  Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

Authors:  Thomas E Witzig; Susan M Geyer; Irene Ghobrial; David J Inwards; Rafael Fonseca; Paul Kurtin; Stephen M Ansell; Ronnie Luyun; Patrick J Flynn; Roscoe F Morton; Shaker R Dakhil; Howard Gross; Scott H Kaufmann
Journal:  J Clin Oncol       Date:  2005-06-27       Impact factor: 44.544

5.  Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.

Authors:  Michael Wang; Yasuhiro Oki; Barbara Pro; Jorge Enrique Romaguera; Maria Alma Rodriguez; Felipe Samaniego; Peter McLaughlin; Frederick Hagemeister; Sattva Neelapu; Amanda Copeland; Barry I Samuels; Evelyne M Loyer; Yuan Ji; Anas Younes
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

Review 6.  The current therapeutic scenario for relapsed mantle cell lymphoma.

Authors:  Simone Ferrero; Martin Dreyling
Journal:  Curr Opin Oncol       Date:  2013-09       Impact factor: 3.645

7.  Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Authors:  Georg Hess; Raoul Herbrecht; Jorge Romaguera; Gregor Verhoef; Michael Crump; Christian Gisselbrecht; Anna Laurell; Fritz Offner; Andrew Strahs; Anna Berkenblit; Orysia Hanushevsky; Jill Clancy; Becker Hewes; Laurence Moore; Bertrand Coiffier
Journal:  J Clin Oncol       Date:  2009-07-06       Impact factor: 44.544

8.  First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.

Authors:  Reyes Arranz; Ana García-Noblejas; Carlos Grande; Jimena Cannata-Ortiz; José J Sánchez; José-Antonio García-Marco; Concepción Aláez; Javier Pérez-Calvo; Pilar Martínez-Sánchez; Blanca Sánchez-González; Miguel-Angel Canales; Eulogio Conde; Alejandro Martín; Eva Arranz; María-José Terol; Antonio Salar; Dolores Caballero
Journal:  Haematologica       Date:  2013-06-10       Impact factor: 9.941

9.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

10.  Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.

Authors:  P L Zinzani; J M Vose; M S Czuczman; C B Reeder; C Haioun; J Polikoff; H Tilly; L Zhang; K Prandi; J Li; T E Witzig
Journal:  Ann Oncol       Date:  2013-09-12       Impact factor: 32.976
View more
  2 in total

1.  Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer.

Authors:  Aurelie Maisonial-Besset; Tiffany Witkowski; Isabelle Navarro-Teulon; Odile Berthier-Vergnes; Giovanna Fois; Yingying Zhu; Sophie Besse; Olivia Bawa; Arnaud Briat; Mercedes Quintana; Alexandre Pichard; Mathilde Bonnet; Eric Rubinstein; Jean-Pierre Pouget; Paule Opolon; Lydia Maigne; Elisabeth Miot-Noirault; Jean-Michel Chezal; Claude Boucheix; Françoise Degoul
Journal:  Oncotarget       Date:  2017-03-28

2.  Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry.

Authors:  Karin Hohloch; Christine Windemuth-Kieselbach; Pier Luigi Zinzani; Roberto Cacchione; Wojciech Jurczak; C Suh; Lorenz Trümper; Christian W Scholz
Journal:  Ann Hematol       Date:  2020-03-03       Impact factor: 3.673
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.